SCHEMBL898265

SCHEMBL898265

O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(-c2ccc(Cl)cc2)oc1C(F)(F)F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX1 P51575 8/20 0.57
TMPRSS4 Q9NRS4 6/20 0.57
P2RX4 Q99571 5/20 0.57
P2RX7 Q99572 5/20 0.57
MEN1 O00255 1/20 0.57
IKBKB O14920 1/20 0.57
CHUK O15111 1/20 0.57
KDR P35968 1/20 0.57
FLT3 P36888 1/20 0.57
KMT2A Q03164 1/20 0.57
MYLK Q15746 1/20 0.57
MAP4K5 Q9Y4K4 1/20 0.57
KDM4E B2RXH2 2/20 0.55
MAPT P10636 2/20 0.55
MCHR1 Q99705 1/20 0.53
XPO1 O14980 1/20 0.49
JUN P05412 4/20 0.46
NFKB1 P19838 4/20 0.46
NFKB2 Q00653 4/20 0.46
RELA Q04206 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL898601 0.93 KDM4E (0.52) P2RX1TMPRSS4P2RX4P2RX7MEN1
SCHEMBL16171175 0.92 KDM4E (0.54) P2RX1TMPRSS4P2RX4P2RX7MEN1
SCHEMBL14927284 0.88 KDM4E (0.55) P2RX1TMPRSS4P2RX4P2RX7MEN1
SCHEMBL899044 0.88 TMPRSS4 (0.57) P2RX1TMPRSS4P2RX4P2RX7MEN1
SCHEMBL902999 0.88 P2RX1 (0.57) P2RX1TMPRSS4P2RX4P2RX7KDM4E
SCHEMBL14927282 0.87 KDM4E (0.57) P2RX1TMPRSS4KDM4EMAPTMCHR1
SCHEMBL14930776 0.86 P2RX1 (0.61) P2RX1TMPRSS4P2RX4P2RX7KDM4E
SCHEMBL902905 0.86 KDM4E (0.48) P2RX1TMPRSS4P2RX4P2RX7MEN1
SCHEMBL17470405 0.85 P2RX1 (0.54) P2RX1TMPRSS4P2RX4P2RX7MEN1
SCHEMBL313321 0.85 MAPT (0.57) P2RX1TMPRSS4P2RX4P2RX7KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2576532-B1 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX LLC (US) 2018-07-18 EP disclosed
EP-2576532-B1 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX LLC (US) 2018-07-18 EP disclosed
US-9663483-B2 Furanyl compounds and the use thereof NOVOMEDIX, LLC (US) 2017-05-30 US disclosed
US-9663483-B2 Furanyl compounds and the use thereof NOVOMEDIX, LLC (US) 2017-05-30 US disclosed
US-20160024040-A1 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX, LLC 2016-01-28 US disclosed
US-20160024040-A1 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX, LLC 2016-01-28 US disclosed
US-9149527-B2 Furanyl compounds and the use thereof NOVOMEDIX, LLC (US) 2015-10-06 US disclosed
US-9149527-B2 Furanyl compounds and the use thereof NOVOMEDIX, LLC (US) 2015-10-06 US disclosed
US-9149527-B2 Furanyl compounds and the use thereof NOVOMEDIX, LLC (US) 2015-10-06 US disclosed
US-20140309297-A1 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX, LLC (US) 2014-10-16 US disclosed
US-20140309297-A1 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX, LLC (US) 2014-10-16 US disclosed
US-8722731-B2 Furanyl compounds and the use thereof NOVOMEDIX, LLC (US) 2014-05-13 US disclosed
US-8722731-B2 Furanyl compounds and the use thereof NOVOMEDIX, LLC (US) 2014-05-13 US disclosed
US-20130116317-A1 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX, LLC (US) 2013-05-09 US disclosed
US-20130116317-A1 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX, LLC (US) 2013-05-09 US disclosed
EP-2576532-A1 FURANYL COMPOUNDS AND THE USE THEREOF Novomedix, LLC (US) 2013-04-10 EP disclosed
WO-2011156321-A9 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX, LLC (US) 2012-04-05 WO disclosed
WO-2011156321-A9 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX, LLC (US) 2012-04-05 WO disclosed
WO-2011156321-A1 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX, LLC (US) 2011-12-15 WO disclosed
WO-2011156321-A1 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX, LLC (US) 2011-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116317-A1 FURANYL COMPOUNDS AND THE USE THEREOF EIF4EBP1, EIF4E, EIF4A1 P2RX1 3876/4885TMPRSS4 4354/4885P2RX4 4189/4885
US-20160024040-A1 FURANYL COMPOUNDS AND THE USE THEREOF EIF4EBP1, EIF4E, GLI1 P2RX1 3867/4885TMPRSS4 4128/4885P2RX4 4158/4885
US-20140309297-A1 FURANYL COMPOUNDS AND THE USE THEREOF EIF4EBP1, EIF4E, GLI1 P2RX1 3867/4885TMPRSS4 4128/4885P2RX4 4158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.